INTELLIGENT ULTRASOUND GROUP PLC

Director's Dealing • Aug 28, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3899K

Intelligent Ultrasound Group PLC

28 August 2019

28 August 2019

Intelligent Ultrasound Group plc

("Intelligent Ultrasound" or the "Company")

Director Dealings

Intelligent Ultrasound (AIM: MED), the intelligent ultrasound software and simulation company, announces that further to the Company's announcements on 8 August 2019 and 27 August 2019, certain Directors have, following Admission today, acquired a total of 500,000 Ordinary Shares in the Company ("Ordinary Shares") via the Placing, as detailed below:

Name	Title	Number of Placing Shares subscribed for#	Value of Placing Shares subscribed for#	Resultant shareholding following subscription#	Percentage of enlarged share capital following subscription#
Stuart Gall	Chief Executive Officer	200,000	£20,000	828,236	0.38%
Wilson Jennings	Finance Director	100,000	£10,000	394,118	0.18%
Nicholas Sleep	Chief Technology Officer	100,000	£10,000	326,471	0.15%
Ian Whittaker	Chief Operating Officer	25,000	£2,500	374,982	0.17%
Nick Avis	Non-Executive Director	25,000	£2,500	225,000	0.10%
Nazar Amso	Non-Executive Director	50,000	£5,000	1,134,000	0.52%

In addition to the above:

Professor Nazar Amso is the beneficial holder of 180,000 Ordinary Shares through The Amso Trust and Professor Nazar Amso's spouse holds 120,000 Ordinary Shares.

# The number of Ordinary Shares presented in this table as being held or subscribed for by Directors refers to the number of Ordinary Shares held or subscribed for by them either personally or through a nominee.

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the circular sent to shareholders of the Company on 8 August 2019.

The Company makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

1.   Stuart Gall

2.   Wilson Jennings

3.   Nicholas Sleep

4.   Ian Whittaker

5.   Nick Avis

6.   Nazar Amso

2

Reason for the notification

a)

Position/status

1.   Chief Executive Officer

2.   Finance Director

3.   Chief Technology Officer

4.   Chief Operating Officer

5.   Non-Executive Director

6.   Non-Executive Director

b)

Initial notification /Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Intelligent Ultrasound Group plc

b)

LEI

213800K4ZVWL4ZYQAZ70

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 1 pence each

ISIN: GB00BN791Q39

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

Price(s)	Volume(s)
1.   10  pence 2.   10  pence 3.   10  pence 4.   10  pence 5.   10  pence 6.   10  pence	1.   200,000 2.   100,000 3.   100,000 4.   25,000 5.   25,000 6.   50,000

d)

Aggregated information

- Aggregated volume

- Price

N/A - single transaction

e)

Date of the transaction

28 August 2019

f)

Place of the transaction

London Stock Exchange, XLON

Enquiries:

Intelligent Ultrasound Group plc	www.intelligentultrasound.com
Stuart Gall, CEO	Tel: +44 (0)29 2075 6534
Cenkos Securities	Tel:  +44 (0)20 7397 8900
Giles Balleny (Nominated Adviser)
Michael Johnson/Julian Morse (Corporate Broking)
Walbrook PR	Tel: +44 (0)20 7933 8780 or intelligentultrasound@walbrookpr.com
Anna Dunphy/Paul McManus	Mob: +44 (0)7876 741 001/Mob: +44 (0)7980 541 893

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHGIGDIBBDBGCI